ICU Vita Pharmaceutical Import Profile — Uruguay (DGFT 2022–2026)

Name: ICU Vita Pharmaceutical Import Records from India — 2 Products, $350.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

ICU Vita — Pharmaceutical Importer Profile (2026) | 2 Products, $350.0K Trade | TransData Nexus

ICU Vita

Pharmaceutical Importer · Uruguay · Antiviral & HIV Medications Focus · $350.0K Total Trade · DGFT Verified

ICU Vita is a pharmaceutical importer based in Uruguay with a total trade value of $350.0K across 2 products in 2 therapeutic categories. Based on 7 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. ICU Vita sources from 1 verified Indian supplier, with Macleods Pharmaceuticals Limited accounting for 100.0% of imports.

ICU Vita — Import Portfolio & Supplier Network

ICU Vita import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to ICU Vita?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Macleods Pharmaceuticals Limited	$657.5K	16	100.0%

ICU Vita sources from 1 verified Indian supplier across 10 distinct formulations. The sourcing is highly concentrated — Macleods Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does ICU Vita Import?

Formulation	Value	Ships
Drugs and pharmaceuticals harmless	$200.0K	4
Lopinavir 200 MG ritonavir 50 MG	$100.0K	2
Medicines. emtricitabine 200MG +	$57.5K	2
Lopinavir 200 MG ritonavir 50 MG	$50.0K	1
Efavirenz 600MG tablets (net content	$50.0K	1
Drugs and pharmaceuticals harmless medicines tenofovir disoproxil fumarate tablets 300 MG	$50.0K	1
Efavirenz 600MG emtricitabine 200MG & tenofovir disoproxil fumarate 300MG tabletbno:bed82306a md.9/23 ed.8/25 ps:1x30s	$50.0K	1
Drugs and pharmaceuticals harmlessmedicines tenofovir disoproxil fumarate tablets 300 MG	$50.0K	1
Lopinavir 200 MG ritonavir 50 MG macleods bno. 14250342a & 14250118c mfg dt:01/2025 exp dt:12/2027 ps: 1x120s	$50.0K	1
Net content 7.8000 kgs emtricitabine	$0	2

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Emtricitabine	Antiviral & HIV Medications	$250.0K	5	0.2%	8
2	Efavirenz	Antivirals	$100.0K	2	0.2%	5

ICU Vita imports 2 pharmaceutical products across 2 categories into Uruguay totaling $350.0K.

ICU Vita — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Laboratorios ICU-VITA is a privately held pharmaceutical manufacturing company headquartered in Montevideo, Uruguay. Established in 1999, the company specializes in the production and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. ICU-VITA plays a significant role in Uruguay's pharmaceutical supply chain, serving as a key supplier to various healthcare providers, including hospitals, clinics, and pharmacies. The company's product portfolio encompasses a range of therapeutic areas, with a notable emphasis on antiviral and HIV medications. ICU-VITA's commitment to quality and regulatory compliance has positioned it as a trusted entity in the Uruguayan pharmaceutical market.

2Distribution Network

ICU-VITA operates a centralized distribution network from its headquarters in Montevideo, Uruguay. The company's logistics capabilities are designed to ensure efficient delivery of pharmaceutical products across the country. While specific warehouse locations are not publicly disclosed, ICU-VITA's distribution infrastructure is structured to meet the demands of the Uruguayan healthcare sector. The company maintains strong relationships with local healthcare providers, facilitating timely and reliable supply of its products. ICU-VITA's distribution network is primarily focused within Uruguay, ensuring comprehensive coverage to meet national healthcare needs.

3Industry Role

In Uruguay's pharmaceutical supply chain, ICU-VITA functions as a primary wholesaler and distributor. The company imports finished pharmaceutical formulations from international suppliers, notably from India, and distributes these products to various healthcare institutions across the country. ICU-VITA's role is pivotal in ensuring the availability of essential medications, particularly in the antiviral and HIV therapeutic categories. By sourcing high-quality products and maintaining a robust distribution network, ICU-VITA contributes significantly to the healthcare infrastructure in Uruguay.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — ICU Vita

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

ICU-VITA's sourcing strategy exhibits a high degree of concentration, with a total import value of $350,000 USD from India over seven shipments. The company's imports are exclusively sourced from a single supplier, MACLEODS PHARMACEUTICALS LIMITED, which has provided all 16 shipments recorded in the customs data. This single-source dependency indicates a strategic choice to maintain a consistent supply of specific pharmaceutical formulations, particularly in the antiviral and HIV medication categories. While this approach can streamline procurement processes and ensure product consistency, it also exposes ICU-VITA to potential risks associated with supply chain disruptions from the sole supplier. The absence of alternative suppliers may impact the company's ability to mitigate risks related to production delays, regulatory changes, or other unforeseen events affecting MACLEODS PHARMACEUTICALS LIMITED.

2Supply Chain Resilience

ICU-VITA's supply chain resilience is closely tied to its exclusive relationship with MACLEODS PHARMACEUTICALS LIMITED. The company's import data indicates a reliance on a single supplier for its pharmaceutical formulations, which may limit its ability to diversify sourcing options. The lack of backup suppliers could pose challenges in the event of supply chain disruptions, such as production delays or regulatory issues affecting MACLEODS PHARMACEUTICALS LIMITED. Additionally, the concentration of shipments from a single supplier may expose ICU-VITA to risks associated with geopolitical factors, trade policies, or other external events impacting the supplier's operations. To enhance supply chain resilience, ICU-VITA may consider exploring alternative suppliers and diversifying its sourcing strategy to mitigate potential risks.

Importing Pharmaceuticals into Uruguay — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Uruguay

1Regulatory Authority & Framework

In Uruguay, the Ministry of Public Health (Ministerio de Salud Pública, MSP) serves as the primary regulatory authority overseeing the pharmaceutical sector. The MSP is responsible for establishing and enforcing regulations related to the importation, production, and marketing of pharmaceutical products. Key legislation governing pharmaceutical imports includes Decree No. 324/999, enacted on October 12, 1999, which regulates the import, representation, production, processing, and marketing of medicines and related products for human use. This decree outlines the requirements for the registration and authorization of pharmaceutical products, ensuring that imported medications meet the necessary safety and efficacy standards. The MSP's regulatory framework aims to protect public health by ensuring that all pharmaceutical products available in Uruguay are of high quality and are appropriately registered and authorized for sale.

2Import Licensing & GMP

To import pharmaceutical products into Uruguay, companies must obtain authorization from the Ministry of Public Health (MSP). This process involves registering the pharmaceutical specialty and obtaining approval for its sale within the country. The registration process requires the submission of detailed product information, including composition, manufacturing processes, and clinical data, to demonstrate the product's safety and efficacy. Additionally, the MSP requires that imported pharmaceutical products comply with Good Manufacturing Practice (GMP) standards. GMP certification from recognized authorities, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, or Pharmaceutical Inspection Co-operation Scheme (PIC/S), is typically recognized by the MSP. Importers must ensure that their suppliers hold valid GMP certifications to facilitate the importation process. Furthermore, companies must obtain wholesale distribution authorization from the MSP, which involves meeting specific requirements related to storage, handling, and distribution practices to ensure the integrity and quality of pharmaceutical products throughout the supply chain.

ICU Vita — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

ICU-VITA's product strategy focuses on importing and distributing pharmaceutical formulations in the antiviral and HIV medication categories. This strategic focus aligns with the company's commitment to addressing critical health needs within Uruguay. The decision to concentrate on these therapeutic areas is driven by the high demand for effective treatments for HIV and related conditions in the country. By sourcing products from reputable manufacturers like Macleods Pharmaceuticals Ltd, ICU-VITA aims to provide high-quality medications that meet international standards. The company's product strategy also reflects a dedication to improving patient outcomes and supporting public health initiatives in Uruguay.

2Sourcing Profile

ICU-VITA's sourcing strategy is characterized by a focus on generic pharmaceutical formulations, particularly in the antiviral and HIV medication categories. The company imports finished pharmaceutical products from a single supplier, Macleods Pharmaceuticals Ltd, based in India. This approach allows ICU-VITA to maintain consistency in product quality and supply. The preference for generic formulations enables the company to offer cost-effective treatment options to the Uruguayan market, making essential medications more accessible to patients. India's robust pharmaceutical manufacturing sector, with its adherence to international quality standards, aligns with ICU-VITA's commitment to providing high-quality products.

Frequently Asked Questions — ICU Vita

What products does ICU Vita import from India?

ICU Vita imports 2 pharmaceutical products across 2 categories. Top imports: Emtricitabine ($250.0K), Efavirenz ($100.0K).

Who supplies pharmaceuticals to ICU Vita from India?

ICU Vita sources from 1 verified Indian suppliers. The primary supplier is Macleods Pharmaceuticals Limited (100.0% of imports, $657.5K).

What is ICU Vita's total pharmaceutical import value?

ICU Vita's total pharmaceutical import value from India is $350.0K, based on 7 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does ICU Vita focus on?

ICU Vita imports across 2 categories. The largest: Antiviral & HIV Medications (71.4%), Antivirals (28.6%).

Get Full ICU Vita Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

ICU Vita

ICU Vita — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to ICU Vita?

What Formulations Does ICU Vita Import?

What Products Does ICU Vita Import?

Top Products by Import Value

ICU Vita Therapeutic Categories — 2 Specializations